| Meredith Delp, DO | |
|
3240 Avalon Pkwy, Conyers, GA 30013-6320 | |
| (770) 860-1133 | |
| (770) 860-1599 |
| Full Name | Meredith Delp |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 15 Years |
| Location | 3240 Avalon Pkwy, Conyers, Georgia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366671752 | NPI | - | NPPES |
| 003136845B | Medicaid | GA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | DO1180 (Alabama) | Secondary |
| 207V00000X | Obstetrics & Gynecology | 70083 (Georgia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dhp Of Georgia Pc | 9931358520 | 6 |
News Archive
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Pramipexole Dihydrochloride Tablets, 0.125 mg, 0.25 mg, 0.5 mg, 1 mg and 1.5 mg, the generic version of Boehringer Ingelheim's Mirapex Tablets, a Parkinson's disease treatment.
In this Journal Sentinel Online opinion piece, Thomas Inglesby, chief executive officer and director of the Center for Biosecurity of UPMC in Baltimore; Anita Cicero, chief operating officer and deputy director of the center; and D.A. Henderson, a distinguished scholar at the center, comment on a recent announcement by scientists that they have genetically modified a strain of H5N1 bird flu that is "capable of spreading through the air between ferrets that were physically separated from each other," indicating "it would be readily transmissible by air between humans."
The Emory Institute of Drug Discovery and Zirus, Inc., a biotechnology company based in Buford, Georgia, have entered into a collaboration and research agreement to develop novel compounds to treat infectious disease. Zirus uses a proprietary method for identifying genes and gene products in host cells that, when blocked, can prevent viruses from multiplying. Over the past several years, either alone or in collaboration with partners, including the Centers for Disease Control and Prevention (CDC), Zirus has identified, licensed and filed patents on more than 1000 targets.
Harris Corporation (NYSE:HRS) reported revenue in the fourth quarter of fiscal 2012 of $1.44 billion compared with $1.52 billion in the prior-year quarter.
Fewer than half of studies conducted on the effects of prescription drugs in children are published in medical journals, according to a study published Wednesday in the Journal of the American Medical Association, the AP/Lexington Herald-Leader reports.
› Verified 8 days ago
| Entity Name | Neighborhood Improvement Project Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700900867 PECOS PAC ID: 7315851078 Enrollment ID: O20031117000665 |
News Archive
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Pramipexole Dihydrochloride Tablets, 0.125 mg, 0.25 mg, 0.5 mg, 1 mg and 1.5 mg, the generic version of Boehringer Ingelheim's Mirapex Tablets, a Parkinson's disease treatment.
In this Journal Sentinel Online opinion piece, Thomas Inglesby, chief executive officer and director of the Center for Biosecurity of UPMC in Baltimore; Anita Cicero, chief operating officer and deputy director of the center; and D.A. Henderson, a distinguished scholar at the center, comment on a recent announcement by scientists that they have genetically modified a strain of H5N1 bird flu that is "capable of spreading through the air between ferrets that were physically separated from each other," indicating "it would be readily transmissible by air between humans."
The Emory Institute of Drug Discovery and Zirus, Inc., a biotechnology company based in Buford, Georgia, have entered into a collaboration and research agreement to develop novel compounds to treat infectious disease. Zirus uses a proprietary method for identifying genes and gene products in host cells that, when blocked, can prevent viruses from multiplying. Over the past several years, either alone or in collaboration with partners, including the Centers for Disease Control and Prevention (CDC), Zirus has identified, licensed and filed patents on more than 1000 targets.
Harris Corporation (NYSE:HRS) reported revenue in the fourth quarter of fiscal 2012 of $1.44 billion compared with $1.52 billion in the prior-year quarter.
Fewer than half of studies conducted on the effects of prescription drugs in children are published in medical journals, according to a study published Wednesday in the Journal of the American Medical Association, the AP/Lexington Herald-Leader reports.
› Verified 8 days ago
| Entity Name | Obhg Georgia, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750686838 PECOS PAC ID: 9032383583 Enrollment ID: O20111117000602 |
News Archive
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Pramipexole Dihydrochloride Tablets, 0.125 mg, 0.25 mg, 0.5 mg, 1 mg and 1.5 mg, the generic version of Boehringer Ingelheim's Mirapex Tablets, a Parkinson's disease treatment.
In this Journal Sentinel Online opinion piece, Thomas Inglesby, chief executive officer and director of the Center for Biosecurity of UPMC in Baltimore; Anita Cicero, chief operating officer and deputy director of the center; and D.A. Henderson, a distinguished scholar at the center, comment on a recent announcement by scientists that they have genetically modified a strain of H5N1 bird flu that is "capable of spreading through the air between ferrets that were physically separated from each other," indicating "it would be readily transmissible by air between humans."
The Emory Institute of Drug Discovery and Zirus, Inc., a biotechnology company based in Buford, Georgia, have entered into a collaboration and research agreement to develop novel compounds to treat infectious disease. Zirus uses a proprietary method for identifying genes and gene products in host cells that, when blocked, can prevent viruses from multiplying. Over the past several years, either alone or in collaboration with partners, including the Centers for Disease Control and Prevention (CDC), Zirus has identified, licensed and filed patents on more than 1000 targets.
Harris Corporation (NYSE:HRS) reported revenue in the fourth quarter of fiscal 2012 of $1.44 billion compared with $1.52 billion in the prior-year quarter.
Fewer than half of studies conducted on the effects of prescription drugs in children are published in medical journals, according to a study published Wednesday in the Journal of the American Medical Association, the AP/Lexington Herald-Leader reports.
› Verified 8 days ago
| Entity Name | Dhp Of Georgia Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578826988 PECOS PAC ID: 9931358520 Enrollment ID: O20120925000305 |
News Archive
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Pramipexole Dihydrochloride Tablets, 0.125 mg, 0.25 mg, 0.5 mg, 1 mg and 1.5 mg, the generic version of Boehringer Ingelheim's Mirapex Tablets, a Parkinson's disease treatment.
In this Journal Sentinel Online opinion piece, Thomas Inglesby, chief executive officer and director of the Center for Biosecurity of UPMC in Baltimore; Anita Cicero, chief operating officer and deputy director of the center; and D.A. Henderson, a distinguished scholar at the center, comment on a recent announcement by scientists that they have genetically modified a strain of H5N1 bird flu that is "capable of spreading through the air between ferrets that were physically separated from each other," indicating "it would be readily transmissible by air between humans."
The Emory Institute of Drug Discovery and Zirus, Inc., a biotechnology company based in Buford, Georgia, have entered into a collaboration and research agreement to develop novel compounds to treat infectious disease. Zirus uses a proprietary method for identifying genes and gene products in host cells that, when blocked, can prevent viruses from multiplying. Over the past several years, either alone or in collaboration with partners, including the Centers for Disease Control and Prevention (CDC), Zirus has identified, licensed and filed patents on more than 1000 targets.
Harris Corporation (NYSE:HRS) reported revenue in the fourth quarter of fiscal 2012 of $1.44 billion compared with $1.52 billion in the prior-year quarter.
Fewer than half of studies conducted on the effects of prescription drugs in children are published in medical journals, according to a study published Wednesday in the Journal of the American Medical Association, the AP/Lexington Herald-Leader reports.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Meredith Delp, DO 3240 Avalon Pkwy, Conyers, GA 30013-6320 Ph: (770) 860-1133 | Meredith Delp, DO 3240 Avalon Pkwy, Conyers, GA 30013-6320 Ph: (770) 860-1133 |
News Archive
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Pramipexole Dihydrochloride Tablets, 0.125 mg, 0.25 mg, 0.5 mg, 1 mg and 1.5 mg, the generic version of Boehringer Ingelheim's Mirapex Tablets, a Parkinson's disease treatment.
In this Journal Sentinel Online opinion piece, Thomas Inglesby, chief executive officer and director of the Center for Biosecurity of UPMC in Baltimore; Anita Cicero, chief operating officer and deputy director of the center; and D.A. Henderson, a distinguished scholar at the center, comment on a recent announcement by scientists that they have genetically modified a strain of H5N1 bird flu that is "capable of spreading through the air between ferrets that were physically separated from each other," indicating "it would be readily transmissible by air between humans."
The Emory Institute of Drug Discovery and Zirus, Inc., a biotechnology company based in Buford, Georgia, have entered into a collaboration and research agreement to develop novel compounds to treat infectious disease. Zirus uses a proprietary method for identifying genes and gene products in host cells that, when blocked, can prevent viruses from multiplying. Over the past several years, either alone or in collaboration with partners, including the Centers for Disease Control and Prevention (CDC), Zirus has identified, licensed and filed patents on more than 1000 targets.
Harris Corporation (NYSE:HRS) reported revenue in the fourth quarter of fiscal 2012 of $1.44 billion compared with $1.52 billion in the prior-year quarter.
Fewer than half of studies conducted on the effects of prescription drugs in children are published in medical journals, according to a study published Wednesday in the Journal of the American Medical Association, the AP/Lexington Herald-Leader reports.
› Verified 8 days ago
Niharika Saini, Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3240 Avalon Blvd, Conyers, GA 30013 Phone: 770-860-1133 | |
Mr. Richard Mark Robinson, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3240 Avalon Blvd, Conyers, GA 30013 Phone: 770-860-1133 Fax: 770-860-1599 | |
Brandi Wood, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3240 Avalon Blvd, Conyers, GA 30013 Phone: 770-860-1133 | |
Dr. Julianne Adams Birt, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1403 Manchester Dr. Ne, Conyers, GA 30012 Phone: 770-860-0123 Fax: 888-868-5181 | |
Megan Sutton Craig, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3240 Avalon Boulevard, Conyers, GA 30013 Phone: 770-860-1133 Fax: 770-860-1599 | |
Dr. Thomas Lewis Lyons, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1380 Milstead Ave Ne, Suite E, Conyers, GA 30012 Phone: 678-609-4913 Fax: 678-609-4923 | |
Dr. Shiraz Habib Kassam, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1380 Milstead Ave Ne Ste B, Conyers, GA 30012 Phone: 770-922-2424 Fax: 770-922-8782 |